PDS Biotechnology (PDSB) Competitors $0.96 -0.06 (-5.62%) Closing price 04:00 PM EasternExtended Trading$0.97 +0.01 (+0.86%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PDSB vs. SXTC, CLLS, FTLF, DERM, BHST, APLT, GNFT, CHRS, PLX, and FBRXShould you be buying PDS Biotechnology stock or one of its competitors? The main competitors of PDS Biotechnology include China SXT Pharmaceuticals (SXTC), Cellectis (CLLS), FitLife Brands (FTLF), Journey Medical (DERM), BioHarvest Sciences (BHST), Applied Therapeutics (APLT), GENFIT (GNFT), Coherus Oncology (CHRS), Protalix BioTherapeutics (PLX), and Forte Biosciences (FBRX). These companies are all part of the "pharmaceutical products" industry. PDS Biotechnology vs. Its Competitors China SXT Pharmaceuticals Cellectis FitLife Brands Journey Medical BioHarvest Sciences Applied Therapeutics GENFIT Coherus Oncology Protalix BioTherapeutics Forte Biosciences China SXT Pharmaceuticals (NASDAQ:SXTC) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk. Which has more risk and volatility, SXTC or PDSB? China SXT Pharmaceuticals has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Do analysts recommend SXTC or PDSB? PDS Biotechnology has a consensus price target of $10.00, suggesting a potential upside of 938.75%. Given PDS Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe PDS Biotechnology is more favorable than China SXT Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00PDS Biotechnology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do institutionals and insiders hold more shares of SXTC or PDSB? 5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Comparatively, 9.2% of PDS Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor SXTC or PDSB? In the previous week, China SXT Pharmaceuticals had 2 more articles in the media than PDS Biotechnology. MarketBeat recorded 2 mentions for China SXT Pharmaceuticals and 0 mentions for PDS Biotechnology. China SXT Pharmaceuticals' average media sentiment score of 0.48 beat PDS Biotechnology's score of 0.00 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment China SXT Pharmaceuticals Neutral PDS Biotechnology Neutral Is SXTC or PDSB more profitable? China SXT Pharmaceuticals' return on equity of 0.00% beat PDS Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets China SXT PharmaceuticalsN/A N/A N/A PDS Biotechnology N/A -184.56%-79.00% Which has higher earnings & valuation, SXTC or PDSB? China SXT Pharmaceuticals has higher revenue and earnings than PDS Biotechnology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChina SXT Pharmaceuticals$1.74M108.69-$3.30MN/AN/APDS BiotechnologyN/AN/A-$37.61M-$0.92-1.05 SummaryChina SXT Pharmaceuticals beats PDS Biotechnology on 7 of the 12 factors compared between the two stocks. Get PDS Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PDSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PDSB vs. The Competition Export to ExcelMetricPDS BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.28M$3.35B$6.10B$10.62BDividend YieldN/A2.28%5.64%4.69%P/E Ratio-1.0522.1685.6627.13Price / SalesN/A265.75527.82206.05Price / CashN/A46.3226.3031.10Price / Book1.899.9612.926.67Net Income-$37.61M-$52.42M$3.30B$276.23M7 Day Performance-4.68%5.95%4.80%3.31%1 Month Performance-19.78%11.59%8.11%10.76%1 Year Performance-74.05%25.01%75.85%33.58% PDS Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PDSBPDS Biotechnology1.7235 of 5 stars$0.96-5.6%$10.00+938.7%-72.5%$45.28MN/A-1.0520SXTCChina SXT Pharmaceuticals0.5403 of 5 stars$1.62-0.6%N/A-71.2%$189.12M$1.74M0.0090Gap DownCLLSCellectis1.4818 of 5 stars$2.84-15.5%$4.00+40.8%+84.8%$186.76M$49.22M-3.46290Positive NewsGap DownHigh Trading VolumeFTLFFitLife Brands3.8517 of 5 stars$19.91+0.2%$23.00+15.5%+23.1%$186.70M$64.47M23.7020DERMJourney Medical1.4999 of 5 stars$7.10+0.6%$12.17+71.4%+12.3%$185.75M$56.13M-18.6890BHSTBioHarvest SciencesN/A$9.96-8.5%$13.67+37.2%N/A$178.87M$30.19M-14.23N/AGap UpAPLTApplied Therapeutics3.6866 of 5 stars$0.61-50.7%$4.13+574.1%-87.0%$178.57M$460K-1.3630High Trading VolumeGNFTGENFIT1.474 of 5 stars$3.65+2.8%$7.00+91.8%-25.7%$177.51M$76.77M0.00120Gap UpCHRSCoherus Oncology4.2957 of 5 stars$1.70+13.3%$4.51+165.4%+57.7%$174.34M$272.21M1.10330PLXProtalix BioTherapeutics2.7547 of 5 stars$2.16+4.9%$15.00+594.4%+125.0%$172.22M$61.95M-16.62200FBRXForte Biosciences3.121 of 5 stars$14.48+4.6%$68.00+369.6%+208.6%$172.07MN/A-0.895Positive News Related Companies and Tools Related Companies SXTC Competitors CLLS Competitors FTLF Competitors DERM Competitors BHST Competitors APLT Competitors GNFT Competitors CHRS Competitors PLX Competitors FBRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PDSB) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredIs This Warren’s Buffett’s #1 AI Investment?Did you know that Warren Buffett is investing in what Jeff Brown believes will be the next generation of artif...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredWall Street legend: “Sell this A.I. stock now”Whats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PDS Biotechnology Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share PDS Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
